Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 18 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Focuses on Long-Term Opportunity as Market Dynamics Evolve
Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid…
-
QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…
-
QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification
BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with…